EP1692318A4 - Compositions and methods to diagnose and treat lung cancer - Google Patents

Compositions and methods to diagnose and treat lung cancer

Info

Publication number
EP1692318A4
EP1692318A4 EP04812984A EP04812984A EP1692318A4 EP 1692318 A4 EP1692318 A4 EP 1692318A4 EP 04812984 A EP04812984 A EP 04812984A EP 04812984 A EP04812984 A EP 04812984A EP 1692318 A4 EP1692318 A4 EP 1692318A4
Authority
EP
European Patent Office
Prior art keywords
diagnose
compositions
methods
lung cancer
treat lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812984A
Other languages
German (de)
French (fr)
Other versions
EP1692318A2 (en
Inventor
Bruce L Roberts
Srinivas Shankara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1692318A2 publication Critical patent/EP1692318A2/en
Publication of EP1692318A4 publication Critical patent/EP1692318A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
EP04812984A 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer Withdrawn EP1692318A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52652803P 2003-12-02 2003-12-02
PCT/US2004/040576 WO2005055808A2 (en) 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer

Publications (2)

Publication Number Publication Date
EP1692318A2 EP1692318A2 (en) 2006-08-23
EP1692318A4 true EP1692318A4 (en) 2008-04-02

Family

ID=34676625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812984A Withdrawn EP1692318A4 (en) 2003-12-02 2004-12-02 Compositions and methods to diagnose and treat lung cancer

Country Status (3)

Country Link
EP (1) EP1692318A4 (en)
JP (1) JP2007518399A (en)
WO (1) WO2005055808A2 (en)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8648052B2 (en) 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
US20150140036A1 (en) 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
JP6779785B2 (en) 2013-12-19 2020-11-04 ノバルティス アーゲー Human mesothelin chimeric antigen receptor and its use
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CN113583129A (en) 2014-03-14 2021-11-02 诺华股份有限公司 Antibody molecules against LAG-3 and uses thereof
EP3119423B1 (en) 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
PE20161371A1 (en) 2014-03-24 2016-12-21 Novartis Ag ORGANIC MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
RU2718542C2 (en) 2014-04-07 2020-04-08 Новартис Аг Treating a malignant tumor using a chimeric antigen cd19 receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
ES2805475T3 (en) 2014-07-21 2021-02-12 Novartis Ag Cancer treatment using a chimeric CD33 antigen receptor
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CN107001316A (en) 2014-08-06 2017-08-01 诺华股份有限公司 It is used as the Carbostyril derivative of antiseptic
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
TW202140557A (en) 2014-08-19 2021-11-01 瑞士商諾華公司 Treatment of cancer using a cd123 chimeric antigen receptor
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
KR20170068504A (en) 2014-10-08 2017-06-19 노파르티스 아게 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CN107001478B (en) 2014-10-14 2022-01-11 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
PE20171044A1 (en) 2014-12-16 2017-07-19 Novartis Ag ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
AU2015374296B2 (en) 2014-12-29 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
BR112017018908A2 (en) 2015-03-10 2018-04-17 Aduro Biotech, Inc. compositions and methods for activating interferon gene stimulator-dependent signaling
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
LT3280729T (en) 2015-04-08 2022-08-10 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (en) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017015427A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
ES2878188T3 (en) 2015-07-29 2021-11-18 Novartis Ag Combination therapies comprising antibody molecules against LAG-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017103895A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3393504A1 (en) 2015-12-22 2018-10-31 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
SG11201805449PA (en) 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
CA3009001A1 (en) 2016-01-11 2017-07-20 Universitat Zurich Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
WO2017140821A1 (en) 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
CN109153714A (en) 2016-03-04 2019-01-04 诺华股份有限公司 Express the cell and application thereof of multiple Chimeric antigen receptor (CAR) molecule
WO2017165681A1 (en) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
DK3433257T3 (en) 2016-03-24 2024-01-02 Novartis Ag ALKYNYL NUCLEOSIDE ANALOGUES AS INHIBITORS OF HUMAN RHINOVIRUS
WO2017216705A1 (en) 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
KR102565885B1 (en) 2016-07-20 2023-08-09 유니버시티 오브 유타 리서치 파운데이션 CD229 CAR T Cells and Methods of Using The Same
TW201811788A (en) 2016-09-09 2018-04-01 瑞士商諾華公司 Polycyclic pyridone compounds as antivirals
WO2018057585A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
AU2017368333A1 (en) 2016-12-03 2019-06-13 Juno Therapeutics, Inc. Methods for determining CAR-T cells dosing
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
CN109071656B (en) 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AR111658A1 (en) 2017-05-05 2019-08-07 Novartis Ag 2-TRICYCLINAL CHINOLINONES AS ANTIBACTERIAL AGENTS
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
CA3065929A1 (en) 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
MX2019014268A (en) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy.
BR112019024291A2 (en) 2017-06-09 2020-07-28 Providence Health & Services-Oregon use of cd39 and cd103 for the identification of reactive human tumor t cells for the treatment of cancer
MX2019015155A (en) 2017-06-29 2020-08-03 Juno Therapeutics Inc Mouse model for assessing toxicities associated with immunotherapies.
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20200116077A (en) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen
US20210132042A1 (en) 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
US20210079015A1 (en) 2017-11-17 2021-03-18 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
JP2021507906A (en) 2017-12-20 2021-02-25 ノバルティス アーゲー Fusion tricyclic pyrazolo-dihydropyrazinyl-pyridone compound as an antiviral agent
JP2021514982A (en) 2018-02-28 2021-06-17 ノバルティス アーゲー Indole-2-carbonyl compounds and their use for the treatment of hepatitis B
WO2019184909A1 (en) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 Novel antibody molecule, and preparation method and use thereof
CN110305210B (en) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 Novel antibody molecules, methods of making and uses thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
JP7361722B2 (en) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド KRAS G12C inhibitors and methods of using the same
MA52501A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20210205449A1 (en) 2018-06-01 2021-07-08 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020012261A (en) 2018-06-12 2021-03-31 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer.
BR112020025048A2 (en) 2018-06-13 2021-04-06 Novartis Ag BCMA CHEMICAL ANTIGEN RECEPTORS AND USES OF THE SAME
WO2020006511A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
JP2021534783A (en) 2018-08-31 2021-12-16 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
KR20210057726A (en) 2018-09-07 2021-05-21 화이자 인코포레이티드 Anti-αvβ8 antibodies and compositions and uses thereof
KR20230170813A (en) 2018-09-12 2023-12-19 노파르티스 아게 Antiviral pyridopyrazinedione compounds
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
JP2022502385A (en) 2018-09-29 2022-01-11 ノバルティス アーゲー Method for producing a compound for inhibiting the activity of SHP2
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020092854A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
JP2022513062A (en) 2018-11-16 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Methods of Dosing Manipulated T Cells to Treat B-Cell Malignancies
JP2020090482A (en) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Improved synthesis of key intermediate of kras g12c inhibitor compound
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20220088070A1 (en) 2018-11-30 2022-03-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
MX2021007104A (en) 2018-12-20 2021-08-11 Amgen Inc Kif18a inhibitors.
EP3898592A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MA54546A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
US20220096651A1 (en) 2019-01-29 2022-03-31 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (en) 2019-03-01 2021-11-30 锐新医药公司 Bicyclic heterocyclic compounds and use thereof
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
CN114340735A (en) 2019-06-28 2022-04-12 璟尚生物制药公司 Antitumor antagonist composed of mutated TGF beta 1-RII extracellular domain and immunoglobulin scaffold
MX2022001296A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
JP2022542394A (en) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Heteroarylamides useful as KIF18A inhibitors
JP2022542967A (en) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド KIF18A inhibitor
CN114391012A (en) 2019-08-02 2022-04-22 美国安进公司 Pyridine derivatives as KIF18A inhibitors
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
BR112022008534A2 (en) 2019-11-04 2022-08-09 Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATE AND METHODS TO TREAT CANCER AND TO TREAT A RAS PROTEIN-RELATED DISORDER
PE20221278A1 (en) 2019-11-04 2022-09-05 Revolution Medicines Inc RAS INHIBITORS
KR20220109407A (en) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. RAS inhibitors
CR20220200A (en) 2019-11-08 2022-07-28 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
BR112022009390A2 (en) 2019-11-14 2022-08-09 Amgen Inc IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C
MX2022006391A (en) 2019-11-26 2022-06-24 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof.
AU2020394441A1 (en) 2019-11-26 2022-06-02 Novartis Ag CD19 and CD22 chimeric antigen receptors and uses thereof
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
CA3179800A1 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
KR20230107617A (en) 2020-11-13 2023-07-17 노파르티스 아게 Combination therapy using chimeric antigen receptor (CAR)-expressing cells
EP4259149A1 (en) 2020-12-08 2023-10-18 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN117616031A (en) 2021-05-05 2024-02-27 锐新医药公司 RAS inhibitors for the treatment of cancer
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
AU2022341239A1 (en) 2021-09-08 2024-03-21 Redona Therapeutics, Inc. Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
TW202342474A (en) 2022-02-14 2023-11-01 美商基利科學股份有限公司 Antiviral pyrazolopyridinone compounds
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032778A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20020146389A1 (en) * 1997-11-18 2002-10-10 Genentech, Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
WO2004073657A2 (en) * 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858204B2 (en) * 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146389A1 (en) * 1997-11-18 2002-10-10 Genentech, Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
WO2000032778A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
WO2004073657A2 (en) * 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ODOUX C ET AL: "Trail, FASL and a blocking anti-DR5antibody augment paclitxed-induced apoptosis in humna non-small-cell lung cancer", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 97, no. 4, February 2002 (2002-02-01), pages 458 - 462, XP002989699, ISSN: 0020-7136 *
SPIERINGS DIANA C J ET AL: "Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 AUG 2003, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3397 - 3405, XP002469336, ISSN: 1078-0432 *
SUN SHI-YONG ET AL: "Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-(3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells", CANCER RESEARCH, vol. 60, no. 24, 15 December 2000 (2000-12-15), pages 7149 - 7155, XP002469335, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2005055808A3 (en) 2006-01-26
WO2005055808A2 (en) 2005-06-23
JP2007518399A (en) 2007-07-12
EP1692318A2 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
EP1692318A4 (en) Compositions and methods to diagnose and treat lung cancer
EP1667680A4 (en) Combination methods of treating cancer
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
SI1583542T1 (en) Compositions and methods for combination antiviral therapy
IL169602A0 (en) Methods of treating lung diseases
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
EP1737482A4 (en) Compositions and methods for treating diseases
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) Methods and compositions
IL176919A0 (en) Methods and compositions for treating cancer
EP1667730A4 (en) Compositions and methods for treating inflammatory lung disease
EP1951050A4 (en) Therapeutic compositions and methods
EP1468118A4 (en) Methods and compositions for treating cancer
EP1778219A4 (en) Ascophyllum compositions and methods
EP1703907A4 (en) Compositions and methods to treat recurrent medical conditions
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
GB0303609D0 (en) Novel therapeutic method and compositions
ZA200508655B (en) Compositions and methods relating to stop-1
GB0308734D0 (en) Uptake of macromolecules
EP1626711A4 (en) Compositions and methods for treating cancer
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1904088A4 (en) Compositions and methods for the treatment of cancer
GB0324523D0 (en) Compositions and methods of treatment
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080229

17Q First examination report despatched

Effective date: 20081023

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090310